Panelists discuss how safety profiles significantly impact both clinical outcomes and economic sustainability in ...

Schizophrenia affects around 23 million people globally, or one in 345 people. The illness can beset sufferers with significant impairment in their personal, social, educational, and occupational ...

Treating schizophrenia with an older, cheaper drug, rather than with heavily promoted newer medications, reduces the cost by as much as 30 percent with no apparent difference in safety and ...

Schizophrenia is a chronic remitting and relapsing mental illness that affects approximately 1.1% of the US population and between 1% and 2% of the Medicaid population. 1,2 Schizophrenia has one of ...